KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
By A. Lièvre, J. Bachet, V. Boige, A. Cayre, D. Le Corre, E. Buc, M. Ychou, O. Bouché, B. Landi, C. Louvet and 9 more. Journal of Clinical Oncology, 2008
1,556 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/13e86e19eb7f6a1cba0f53f07aba04c85b7a62fa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
Citations in the corpus
- In vivo delivery of miRNAs for cancer therapy: Challenges and strategies (2014, background): “Recent evidences showed that EGFR-specific antibodies extended patient survival with colorectal cancer [7,8].”
- EGFR antagonists in cancer treatment. (2008, methodology): “by the Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC).(1-10) Details of the BCBSA TEC assess-”
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value (2013, methodology): “The seven most frequent mutations in codons 12 and 13 of KRAS were assessed as previously described [14].”
- American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. (2009, methodology): “The review of the evidence on which this PCO is based consists primarily of the rigorous systematic review of the literature conducted by the Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC).(1-10) Details of the BCBSA TEC assessment can be found in the full TEC repo”